MAB-CHMINACA (also known as ADB-CHMINACA ) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015.
MAB-CHMINACA is a methylated form of the synthetic cannabinoid AB-CHMINACA . MAB-CHMINACA metabolite M1 is an expected metabolite of MAB-CHMINACA that is monohydroxylated on the cyclohexyl ring. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Originally developed in 2009 by Pfizer with the intention to be tested for analgesic properties, MAB-CHMINACA soon proved to have other features that appeal to advanced researchers. According to the results of initial observations, the substance displays very high affinity for CB1 receptors at 0.289 nM, which is considerably above values measured for some of the conventional synthetic cannabinoids. New product is structurally related to several other indazole-based chemicals including AB-FUMINACA and AB-CHMINACA, but is unique because of a tert-butyl group substituting the isobutyl moiety in the molecular chain. Due to its novelty, little is presently known about the physical and chemical properties of MAB-CHMINACA, and its pharmacological profile will have to be mapped by quantitative research.
Top Cannabinoids Shop is a reliable source of MAB-CHMINACA of very high purity, with guaranteed delivery to specified address anywhere in the world. Please note that local restrictions or regulations could apply to this chemical and verify its current legal status before placing an order. The product may only be used for controlled scientific research under strict supervision of qualified laboratory personnel and is not approved for pharmaceutical or veterinary purposes. Any kind of application outside of in vitro experiments represents a breach of our policies and could have potentially hazardous consequences.
It was first reported in Russia and Belarus in January 2014, but has since been sold in a number of other countries. It is the indole core analogue of 5F-AMB. Synthetic cannabinoid compounds with an indole-3-carboxamide or indazole-3-carboxamide core bearing a N-1-methoxycarbonyl group with attached isopropyl or t-butyl substituent, have proved to be much more dangerous than older synthetic cannabinoid compounds previously reported, and have been linked to a large number of deaths in Russia, Japan, Europe and the United States